SMC1A and breast adenocarcinoma: We did not observe any drastic changes in either morphology or viability, suggesting that the residual SMC1A or NIPBL remaining (after siRNA treatment) in our breast adenocarcinoma cells is enough to maintain our cells in healthy conditions (fig.